Sonnet BioTherapeutics Holdings, Inc. - Common Stock (SONN)
7.7900
-0.8200 (-9.52%)
NASDAQ · Last Trade: Jul 17th, 6:07 PM EDT
Detailed Quote
Previous Close
8.610
Open
8.110
Bid
7.690
Ask
7.750
Day's Range
7.140 - 8.570
52 Week Range
1.080 - 19.30
Volume
2,211,426
Market Cap
24.66M
PE Ratio (TTM)
-0.5753
EPS (TTM)
-13.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
10,709,827
Chart
About Sonnet BioTherapeutics Holdings, Inc. - Common Stock (SONN)
Sonnet Biotherapeutics Holdings Inc is a biotechnology company focused on the development of innovative therapies for various diseases, particularly in the field of immuno-oncology. The company leverages its proprietary technology platform to create biologic drugs that aim to harness the body's immune system to target and eliminate cancer cells. Through a combination of advanced engineering and scientific expertise, Sonnet is working to deliver novel treatments that could provide meaningful benefits to patients in need, addressing unmet medical needs in oncology and other therapeutic areas. Read More
U.S. stocks traded mostly flat on Monday as investors reacted to President Donald Trump's announcement of a 30% tariff on all imports from the EU and Mexico.
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN) and Rorschach I LLC is fair to Sonnet shareholders. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company.
In today’s volatile small-cap landscape, several companies trading under $3 are making bold strategic moves across the consumer health, biotech, industrial, and mobility tech sectors—each positioning for significant growth.
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting.
